334
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus

, , , , &
Pages 363-368 | Received 18 Jan 2013, Accepted 03 Apr 2013, Published online: 24 May 2013

References

  • Boddaert, J., D. L. T. Huong, Z. Amoura, B. Wechsler, P. Godeau, and J. C. Piette. 2004. Late-onset systemic lupus erythematosus. A personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 83: 348–359
  • Mak, A., C. C. Mok, W. P. Chu, C. H. To, S. N. Wong, and T. C. Au. 2007. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus. 16: 28–34
  • Maddison, P. J. 1987. Systemic lupus erythematosus in the elderly. J Rheumatol Suppl. 14: 182–187
  • Formiga, F., I. Moga, M. Pac, F. Mitjavila, A. Rivera, and R. Pujol. 1999. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. SLE Disease Activity Index. Lupus. 8: 462–465
  • Mak, S. K., E. K. Lam, and A. K. Wong. 1998. Clinical profile of patients with late onset SLE: not a benign subgroup. Lupus. 7: 23–28
  • Catoggio, L. J., R. P. Skinner, G. Smith, and P. J. Maddison. 1984. Systemic lupus erythematosus in the elderly: clinical and serological characteristics. J Rheumatol. 11: 175–181
  • Ramos-Casals, M., M. Garcia-Carraso, M. P. Brito, A. Lopez-Soto, and J. Font. 2003. Immunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus. 12: 341–355
  • Pu, S. L., S. F. Luo, Y. J. Wu, H. S. Cheng, and H. H. Ho. 2000. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus. 9: 96–100
  • Appenzeller, S., D. A. Pereira, and L. T. Costellat. 2008. Greater accrual damage in late-onset systemic lupus erythematosus: a long term follow up study. Lupus. 17: 1023–1028
  • Baker, S. B., J. R. Rovira, E. W. Campion, and J. A. Mills. 1979. Late onset systemic lupus erythematosus. Am J Med. 66: 727–732
  • Wilson, H. A., M. E. Hamilton, D. A. Spyker, D. A. Spyker, C. M. Brunner, W. M. o'Brien, J. S. Davis 4th, and J. B. Winfield. 1981. Age influences the clinical and serological expression of systemic lupus erythematosus. Arthritis Rheum. 24: 1230–1235
  • Cervera, K., M. A. Khamashta, J. Font, G. D. Sebastiani, A. Gil, P. Lavilla, J. C. Mejía. 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine 82: 299–308
  • Ward, M. M. and R. P. Polisson. 1989. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum. 32: 1226–1232
  • Padovan, M., M. Govoni, G. Castellino, N. Rizzo, M. Fotinidi, and F. Trotta. 2007. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int. 27:735–741
  • Sayarlioglu, M., A. Cefle, S. Kamali, A. Gul, M. Inanc, L. Ocal, and O. Aral. 2005. Characteristics of patients with late onset systemic lupus erythematosus in Turkey. Int J Clin Pract. 59: 183–187
  • Bertoli, A. M., G. S. Alarcón, J. Calvo-Alén, L. M. Vilá, M. L. Sanchez, J. D. Reveille, G. S. Alarcón, et al; LUMINA study group. 2006. Systemic Lupus Erythematosus in a multiethnic US cohort. XXXIII. Clinical (corrected) features, course and outcome in patients with late onset disease. Arthritis Rheum. 54:1580–1587
  • Maddison, P., V. Farewell, D. Isenberg, Aranow C., S. C. Bae, S. Barr, J. Buyon, et al. 2002. Systemic Lupus International Collaborating Clinics. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol. 29: 913–917
  • Alarcon, G. S., G. McGwin, A. A. Bartolucci, J. Roseman, J. Lisse, B. J. Fessler, H. M. Bastian, et al. 2001. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 44: 2797–2806
  • Lalani, S., J. Pope, F. de Leon, C. Peschken, and the Members of CaNIOS/1000 Faces of Lupus. 2010. Clinical features and prognosis of late-onset systemic Lupus Erythematosus: results from the 1000 faces of Lupus study. Lupus 37:38–44
  • Alarcon, G. S., G. McGwin, H. M. Bastian, Roseman J., J. Lisse, B. J. Fessler, A. W. Friedman, et al. 2001. For the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. VII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum. 45: 191–202
  • Hochberg, M. C. 1997. Updating the American College of Rheumatology revised criteria for the classification of Systemic Lupus erythematosus. Arthritis Rheum. 40:1725
  • Bernstein, R. M., C. C. Bunn, and G. R. V. Hughes. 1982. Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. Ann Rheum Dis. 41: 554–555
  • Clark, G., M. Reichlin, and T. B. Tomasi. 1969. Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol. 102:117–122
  • Venables, P. J. W., P. R. Smith, and R. N. Maini. 1983. Purification and characterization of the Sjögren’s Syndrome A and B antigens. Clin Exp Immunol. 54:731–738
  • Riboldi, P., M. Gerosa, G. Moroni, A. Radice, F. Allegri, A. Sinico, A. Tincani, et al. 2005. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 38:39–45
  • Harris, E. N. 1990. The Second International anti-cardiolipin standardization workshop. The Kingston anti-phospholipid antibody study (KAPS) group. Ann J Clin Pathol. 94: 476–484
  • Balestrieri, G., A. Tincani, L. Spatola, F. Allegri, E. Prati, R. Cattaneo, G. Valesini, et al. 1995. Anti-ß2 glycoprotein I: a marker of antiphospholipid syndrome? Lupus 4:122–130
  • Vitali, C., W. Bencivelli, S. Bombardieri, D. A. Isenberg, J. S. Smolen, M. L. Snaith, M. Sciuto, et al. 1992. The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol. 10:541–547
  • Bertoli, A. M., G. S. Alarcón, J. Calvo-Alén, M. Fernández, L. M. Vilá, and J. D. Reveille. 2006. LUMINA study group. Systemic Lupus Erythematosus in a multiethnic US cohort. XXXIII. Clinical (corrected) features, course and outcome in patients with late onset disease. Arthritis Rheum. 54: 1580–1587
  • Franceschini, F. and I. Cavazzana. 2005. Anti-Ro/SSA and anti-La/SSB antibodies. Autoimmunity 38: 55–63
  • Font, J., L. Pallarés, R. Cervera, A. López-Soto, M. Navarro, X. Bosch, and M. Ingelmo. 1991. Systemic Lupus Erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 50: 702–705
  • Truedsson, L., A. A. Vengtsson, and G. Sturfelt. 2007. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40: 560–566
  • Karoubi Nordon, E., G. Hayem, F. Mentres, E. Palazzo, S. Legrain, O. Meyer, and P. Raveau. 2007. Late onset systemic lupus erythematosus: a new approach. Lupus 16:1011–1014
  • Manger, K., B. Manger, R. Repp, M. Geisselbrecht, A. Geiger, A. Pfahlberg, T. Harrer, et al. 2002. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 61: 1065–1070
  • Alarçon, G. S., G. McGwin, A. M. Bertoli, B. J. Fessler, J. Calvo-Alén, H. M. Bastian, L. M. Vilá, et al. 2007. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multi-ethnic US cohort (LUMINA L). Ann Rheum Dis. 66: 1168–1172
  • Ruiz-Irastorza, G., M.-V. Egurbide, J.-I. Pijon, M. Garmendia, I. Villar, A. Martinez-Berriotxoa, J. G. Erdozain, et al. 2006. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 15:577–586
  • Wahl, D. G., H. Bounameaux, P. de Moerloose, and F. P. Sarasin. 2000. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefit outweigh the risks? A decision analysis. Arch Int Med. 160: 2042–2048
  • Leung, M. H., S. Heaton, J. Skan. 2002. Mortality and malignancy in the multi-ethnic Birmingham Lupus Cohort-aspirin use is beneficial and non-Caucasian origin is not associated with a poor outcome. Rheumatology 41: S17
  • Dimant, J., E. M. Ginzler, M. Sclesinger, H. S. Diamond, and D. Kaplan. 1979. Systemic lupus erythematosus in the older age group: computer analysis. J Am Geriatr Soc. 27: 58–61
  • Ward, M. M., E. Pyunn, and S. Studenski. 1995. Causes of death in systemic lupus erythematosus. Long term follow-up of an inception cohort. Arthritis Rheum. 38: 1492–1499
  • Asanuma, Y., A. Oeser, A. K. Shintani, E. Turner, N. Olsen, S. Fazio, M. F. Linton, et al. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 349: 2407–2415
  • Urowitz, M.B., D. Galdman, D. Ibanez, S. C. Bae, J. Sanchez-Guerrero, C. Gordon, A. Clarke, et al. 2010. Atherosclerotic vascular events in a multinational Inception cohort of systemic lupus erythematosus. Arthritis Care Res. 62: 881–887
  • Sherer, Y., H. Zinger, and Y. Shoenfeld. 2010. Atherosclerosis in systemic lupus erythematosus. Autoimmunity 43:98–102
  • Kaplan, M. J. 2009. Premature vascular damage in systemic lupus erythematosus. Autoimmunity 42:580–586

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.